基于连花清瘟胶囊中西医结合治疗早期新型冠状病毒肺炎的临床研究

[目的] 通过对新型冠状病毒肺炎（COVID-19）确诊患者进行回顾性研究，评价连花清瘟胶囊早期介入的临床疗效，为临床治疗提供参考依据。[方法] 收集2020年1月22日—2月23日，天津地区COVID-19出院患者的临床资料，根据当时采取的治疗手段，筛选连花清瘟早期治疗组（治疗组）24例，中西医常规治疗组（常规组） 23例，比较两组临床主要症状（发热、乏力、咳嗽、咯痰）消失时间、体温复常及住院天数、计算机断层扫描（CT）影像好转率及临床症状评分。[结果] 与常规组比较，治疗组咳嗽症状改善率为66.7%（常规组53.3%），乏力症状改善率为100%（常规组42.1%），咯痰症状改善率为33.3%（常规组66.7%），其中乏力症状消失情况组间比较差异有统计学意义（P<0.05）；两组发热症状消失率均为100%，治疗组体温复常天数为（3.5±1.8） d，常规组（6.8±3.1） d，两组比较差异有统计学意义（P<0.05），比较两组CT影像好转率，治疗组为87.5%，常规组为78.2%，差异具有统计学意义（P<0.05），治疗组临床症状评分较常规组改善明显，差异有统计学意义（P<0.05）。[结论] 在COVID-19患者早期介入连花清瘟胶囊（颗粒），能改善COVID-19患者临床症状及影像学变化，缩短体温复常时间，为中西医更密切、更便捷的结合治疗提供了临床研究思路。

Clinical study on the treatment of early COVID-19 based on Lianhua Qingwen Capsule with integrated Chinese and Western medicine

[Objective] To evaluate the clinical effect of Lianhua Qingwen Capsules in the early complementary treatment of the disease through the retrospective study of the patients diagnosed with COVID-19 and to provide reference for clinical treatment.[Methods] According to the treatment methods, the patients with COVID-19 in Tianjin from January 22 to February 23, 2020, were divided into Lianhua Qingwen Capsules therapy group(24 cases) and the control group(23 cases). The time of the major symptom(fever, fatigue, cough, expectoration) disappearance, the length of hospital stay, the days for temperature return to normal and clinical syndrome score were compared. [Results] Compared with the control group, the disappearance rate of cough symptoms in the therapy group was 66.7%(53.3% in the control group), the disappearance rate of fatigue symptoms was 100%(42.1% in the control group), the disappearance rate of expectoration symptoms was 33.3%(66.7% in the control group), and the disappearance rate of fatigue symptoms intwo groups was statistically significant(P<0.05). The disappearance rate of fever symptoms in both groups was 100%. The number of days for body temperature to return to normal in the therapy group was(3.5±1.8) d and that in the control group was(6.8±3.1) d. The difference between two groups was statistically significant(P<0.05). The improvement rate of CT images in the treatment group was 87.5%, and the control group was 78.2%. The difference was statistically significant(P<0.05). The clinical symptom score of the therapy group was significantly improved compared with the control group, and the difference was statistically significant(P<0.05). [Conclusion] Lianhua Qingwen Capsules(Granules) in the early stage of patients with COVID-19 can effectively reduce the clinical symptoms and the CT performance, shorten the time of temperature return to normal, and provide clinical research evidence for combination of western and traditional Chinese medicine more closer and more convenient.